Lan Gaochen, Li Jie, Wen Qiaomei, Lin Lin, Chen Libin, Chen Liyu, Chen Xi
Department of Oncology, Fujian Tingzhou Hospital, Longyan, Fujian 366300, P.R. China.
Department of Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian 350025, P.R. China.
Oncol Lett. 2018 Apr;15(4):5093-5097. doi: 10.3892/ol.2018.7991. Epub 2018 Feb 7.
Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) serves an important role in inhibiting anti-tumor immune response in the majority of solid tumors. However, a limited number of studies reported the function of CTLA-4 in luminal B HER2-negative breast cancer. Immunohistochemistry was performed to evaluate the expression of tumor and interstitial CTLA-4 in luminal B HER2-negative breast cancer tissues. The percentage of patients with tumor and interstitial CTLA-4 was 41.2% (42/102) and 46.1% (47/102), respectively. There was a positive association between tumor CTLA-4 expression and interstitial CTLA-4 expression (P<0.05). The disease-free survival (DFS) of the tumor CTLA-4 group was significantly shorter compared with patients with tumor CTLA-4 (mean, 89.070 vs. 39.022 months; P<0.0001). Additionally, the DFS of interstitial CTLA-4 group was shorter compared with the interstitial CTLA-4 group (mean, 85.526 vs. 46.574 months; P<0.0001). Tumor and interstitial CTLA-4 expression may have prognostic predicting value in luminal B HER2-negative breast cancer. The present study may provide the basis for the use of a CTLA-4 blocker in patients with luminal B HER2-negative breast cancer.
细胞毒性T淋巴细胞相关抗原4（CTLA-4）在大多数实体瘤的抗肿瘤免疫反应抑制中发挥重要作用。然而，仅有少数研究报道了CTLA-4在腔面B型HER2阴性乳腺癌中的功能。采用免疫组织化学方法评估腔面B型HER2阴性乳腺癌组织中肿瘤及间质CTLA-4的表达情况。肿瘤及间质CTLA-4阳性患者的比例分别为41.2%（42/102）和46.1%（47/102）。肿瘤CTLA-4表达与间质CTLA-4表达之间存在正相关（P<0.05）。肿瘤CTLA-4阳性组的无病生存期（DFS）显著短于肿瘤CTLA-4阴性患者（平均89.070个月对39.022个月；P<0.0001）。此外，间质CTLA-4阳性组的DFS短于间质CTLA-4阴性组（平均85.526个月对46.574个月；P<0.0001）。肿瘤及间质CTLA-4表达可能对腔面B型HER2阴性乳腺癌具有预后预测价值。本研究可能为腔面B型HER2阴性乳腺癌患者使用CTLA-4阻断剂提供依据。
